Insider Stock Trading History of Doberstein Stephen K


The following table details the trading activities (stock purchases, stock sales, and stock option exercises) reported to the Securities and Exchange Commission (SEC) by insider Doberstein Stephen K since year 2005. The trader's CIK number is 1480111. At the time of this reporting, Doberstein Stephen K is the SVP & Chief Scientific Officer of Nektar Therapeutics . (stock ticker symbol NKTR). See this page for all insider trading activities at Nektar Therapeutics .


Stock purchases, sales, and option exercises reported by insider Doberstein Stephen K since 2005.
  Trade Date   Symbol Company Name (Issuer) Trade Type     Shares       Price ($)   Value ($)
2017-11-06 NKTR Nektar Therapeutics Sale 20,914 24.98 522,431
2017-11-08 NKTR Nektar Therapeutics Option Ex 300,000 9.53 2,859,000
2017-11-07 NKTR Nektar Therapeutics Sale 75,409 25.78 1,944,044
2017-11-08 NKTR Nektar Therapeutics Sale 300,000 30.09 9,027,000
2017-11-06 NKTR Nektar Therapeutics Option Ex 20,914 9.53 199,310
2017-11-07 NKTR Nektar Therapeutics Option Ex 75,409 9.53 718,647
2017-10-05 NKTR Nektar Therapeutics Option Ex 43,677 9.53 416,241
2017-10-05 NKTR Nektar Therapeutics Sale 43,677 24.97 1,090,614
2017-08-16 NKTR Nektar Therapeutics Sale 1,701 19.32 32,863
2017-05-16 NKTR Nektar Therapeutics Sale 1,701 19.55 33,254
2017-04-05 NKTR Nektar Therapeutics Option Ex 100,000 9.53 952,999
2017-04-05 NKTR Nektar Therapeutics Sale 100,000 21.70 2,170,000
2017-02-16 NKTR Nektar Therapeutics Sale 1,261 13.14 16,569
2016-11-16 NKTR Nektar Therapeutics Sale 670 13.96 9,353
2016-08-16 NKTR Nektar Therapeutics Sale 1,336 17.56 23,460
2016-05-16 NKTR Nektar Therapeutics Option Ex 875 .00 0
2016-05-17 NKTR Nektar Therapeutics Sale 339 13.58 4,603
2016-02-16 NKTR Nektar Therapeutics Option Ex 875 .00 0
2016-02-17 NKTR Nektar Therapeutics Sale 390 11.92 4,648

Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Doberstein Stephen K (SVP & Chief Scientific Officer of Nektar Therapeutics at the time of this reporting) see the Securities and Exchange Commission (SEC) website.